喜讯!中国**靶向CD30的抗体药物偶联物ADCETRIS(brentuximab vedotin)获得批准

2020-05-16 Allan MedSci原创

武田中国今日宣布,靶向CD30的ADCETRIS(brentuximab vedotin)已获得中国国家药品监督管理局(NMPA)的正式批准。

武田中国今日宣布,靶向CD30的ADCETRIS(brentuximab vedotin)已获得中国国家药品监督管理局(NMPA)的正式批准,可用于治疗复发性或难治性系统性间变性大细胞淋巴瘤(sALCL)或CD30阳性霍奇金淋巴瘤患者。

中国ADCETRIS注册研究的首席研究员朱军教授说:“我们预计,brentuximab vedotin将为中国CD30阳性淋巴瘤患者提供更好的治疗选择。sALCL和经典霍奇金淋巴瘤都是表达CD30的淋巴瘤亚型。几十年来,中国复发或难治性淋巴瘤患者的治疗选择非常有限。患者的总生存率低,生活质量很差”。

淋巴瘤是一种起源于淋巴造血系统的恶性肿瘤,是淋巴瘤家族中70多个亚型的统称。它是中国死亡率最高的十大恶性肿瘤之一。数据显示,在中国,每年大约有9.3万人被诊断出患有淋巴瘤,其中有50,000多人因此而死亡。目前,在中国,用于治疗复发性或难治性淋巴瘤患者的疗法非常有限。

 

原始出处:

https://www.firstwordpharma.com/node/1724828

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2036843, encodeId=a6d4203684366, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4304, encryptionId=f3f34304f2, topicName=CD30)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 13 04:19:06 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016180, encodeId=307520161808c, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Dec 28 06:19:06 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957632, encodeId=3d5a195e632d0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Fri Dec 11 07:19:06 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912363, encodeId=65b619123632c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Nov 01 20:19:06 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947278, encodeId=1189194e27868, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Wed Sep 30 15:19:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811415, encodeId=66e0181141541, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88032, encryptionId=26ae8803219, topicName=获得批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Tue Jul 28 13:19:06 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413827, encodeId=0916141382e40, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423360, encodeId=f578142336033, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3720, encryptionId=f23c3e206c, topicName=Brentuximab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3be3772079, createdName=photoman, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527042, encodeId=b865152e042bb, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2021-02-13 xirongguo
  2. [GetPortalCommentsPageByObjectIdResponse(id=2036843, encodeId=a6d4203684366, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4304, encryptionId=f3f34304f2, topicName=CD30)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 13 04:19:06 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016180, encodeId=307520161808c, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Dec 28 06:19:06 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957632, encodeId=3d5a195e632d0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Fri Dec 11 07:19:06 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912363, encodeId=65b619123632c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Nov 01 20:19:06 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947278, encodeId=1189194e27868, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Wed Sep 30 15:19:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811415, encodeId=66e0181141541, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88032, encryptionId=26ae8803219, topicName=获得批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Tue Jul 28 13:19:06 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413827, encodeId=0916141382e40, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423360, encodeId=f578142336033, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3720, encryptionId=f23c3e206c, topicName=Brentuximab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3be3772079, createdName=photoman, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527042, encodeId=b865152e042bb, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2036843, encodeId=a6d4203684366, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4304, encryptionId=f3f34304f2, topicName=CD30)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 13 04:19:06 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016180, encodeId=307520161808c, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Dec 28 06:19:06 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957632, encodeId=3d5a195e632d0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Fri Dec 11 07:19:06 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912363, encodeId=65b619123632c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Nov 01 20:19:06 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947278, encodeId=1189194e27868, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Wed Sep 30 15:19:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811415, encodeId=66e0181141541, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88032, encryptionId=26ae8803219, topicName=获得批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Tue Jul 28 13:19:06 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413827, encodeId=0916141382e40, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423360, encodeId=f578142336033, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3720, encryptionId=f23c3e206c, topicName=Brentuximab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3be3772079, createdName=photoman, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527042, encodeId=b865152e042bb, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2036843, encodeId=a6d4203684366, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4304, encryptionId=f3f34304f2, topicName=CD30)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 13 04:19:06 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016180, encodeId=307520161808c, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Dec 28 06:19:06 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957632, encodeId=3d5a195e632d0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Fri Dec 11 07:19:06 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912363, encodeId=65b619123632c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Nov 01 20:19:06 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947278, encodeId=1189194e27868, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Wed Sep 30 15:19:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811415, encodeId=66e0181141541, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88032, encryptionId=26ae8803219, topicName=获得批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Tue Jul 28 13:19:06 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413827, encodeId=0916141382e40, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423360, encodeId=f578142336033, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3720, encryptionId=f23c3e206c, topicName=Brentuximab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3be3772079, createdName=photoman, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527042, encodeId=b865152e042bb, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
    2020-11-01 snf701207
  5. [GetPortalCommentsPageByObjectIdResponse(id=2036843, encodeId=a6d4203684366, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4304, encryptionId=f3f34304f2, topicName=CD30)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 13 04:19:06 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016180, encodeId=307520161808c, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Dec 28 06:19:06 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957632, encodeId=3d5a195e632d0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Fri Dec 11 07:19:06 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912363, encodeId=65b619123632c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Nov 01 20:19:06 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947278, encodeId=1189194e27868, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Wed Sep 30 15:19:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811415, encodeId=66e0181141541, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88032, encryptionId=26ae8803219, topicName=获得批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Tue Jul 28 13:19:06 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413827, encodeId=0916141382e40, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423360, encodeId=f578142336033, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3720, encryptionId=f23c3e206c, topicName=Brentuximab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3be3772079, createdName=photoman, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527042, encodeId=b865152e042bb, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2036843, encodeId=a6d4203684366, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4304, encryptionId=f3f34304f2, topicName=CD30)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 13 04:19:06 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016180, encodeId=307520161808c, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Dec 28 06:19:06 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957632, encodeId=3d5a195e632d0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Fri Dec 11 07:19:06 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912363, encodeId=65b619123632c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Nov 01 20:19:06 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947278, encodeId=1189194e27868, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Wed Sep 30 15:19:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811415, encodeId=66e0181141541, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88032, encryptionId=26ae8803219, topicName=获得批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Tue Jul 28 13:19:06 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413827, encodeId=0916141382e40, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423360, encodeId=f578142336033, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3720, encryptionId=f23c3e206c, topicName=Brentuximab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3be3772079, createdName=photoman, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527042, encodeId=b865152e042bb, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2036843, encodeId=a6d4203684366, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4304, encryptionId=f3f34304f2, topicName=CD30)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 13 04:19:06 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016180, encodeId=307520161808c, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Dec 28 06:19:06 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957632, encodeId=3d5a195e632d0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Fri Dec 11 07:19:06 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912363, encodeId=65b619123632c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Nov 01 20:19:06 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947278, encodeId=1189194e27868, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Wed Sep 30 15:19:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811415, encodeId=66e0181141541, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88032, encryptionId=26ae8803219, topicName=获得批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Tue Jul 28 13:19:06 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413827, encodeId=0916141382e40, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423360, encodeId=f578142336033, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3720, encryptionId=f23c3e206c, topicName=Brentuximab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3be3772079, createdName=photoman, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527042, encodeId=b865152e042bb, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2036843, encodeId=a6d4203684366, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4304, encryptionId=f3f34304f2, topicName=CD30)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 13 04:19:06 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016180, encodeId=307520161808c, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Dec 28 06:19:06 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957632, encodeId=3d5a195e632d0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Fri Dec 11 07:19:06 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912363, encodeId=65b619123632c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Nov 01 20:19:06 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947278, encodeId=1189194e27868, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Wed Sep 30 15:19:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811415, encodeId=66e0181141541, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88032, encryptionId=26ae8803219, topicName=获得批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Tue Jul 28 13:19:06 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413827, encodeId=0916141382e40, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423360, encodeId=f578142336033, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3720, encryptionId=f23c3e206c, topicName=Brentuximab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3be3772079, createdName=photoman, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527042, encodeId=b865152e042bb, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2036843, encodeId=a6d4203684366, content=<a href='/topic/show?id=f3f34304f2' target=_blank style='color:#2F92EE;'>#CD30#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4304, encryptionId=f3f34304f2, topicName=CD30)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sat Feb 13 04:19:06 CST 2021, time=2021-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016180, encodeId=307520161808c, content=<a href='/topic/show?id=d0565520072' target=_blank style='color:#2F92EE;'>#抗体药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55200, encryptionId=d0565520072, topicName=抗体药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Mon Dec 28 06:19:06 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1957632, encodeId=3d5a195e632d0, content=<a href='/topic/show?id=a09c551998a' target=_blank style='color:#2F92EE;'>#抗体药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55199, encryptionId=a09c551998a, topicName=抗体药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=793a2500200, createdName=12498e5fm12(暂无昵称), createdTime=Fri Dec 11 07:19:06 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912363, encodeId=65b619123632c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Nov 01 20:19:06 CST 2020, time=2020-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947278, encodeId=1189194e27868, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Wed Sep 30 15:19:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1811415, encodeId=66e0181141541, content=<a href='/topic/show?id=26ae8803219' target=_blank style='color:#2F92EE;'>#获得批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88032, encryptionId=26ae8803219, topicName=获得批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=838d2500169, createdName=12498cb5m13暂无昵称, createdTime=Tue Jul 28 13:19:06 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413827, encodeId=0916141382e40, content=<a href='/topic/show?id=ce4a55202f0' target=_blank style='color:#2F92EE;'>#抗体药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55202, encryptionId=ce4a55202f0, topicName=抗体药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f5ea3025344, createdName=chendoc243, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423360, encodeId=f578142336033, content=<a href='/topic/show?id=f23c3e206c' target=_blank style='color:#2F92EE;'>#Brentuximab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3720, encryptionId=f23c3e206c, topicName=Brentuximab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3be3772079, createdName=photoman, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1527042, encodeId=b865152e042bb, content=<a href='/topic/show?id=302e18332e1' target=_blank style='color:#2F92EE;'>#vedotin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18332, encryptionId=302e18332e1, topicName=vedotin)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=620c11794019, createdName=jiangfeng5071, createdTime=Mon May 18 02:19:06 CST 2020, time=2020-05-18, status=1, ipAttribution=)]

相关资讯

Lancet oncol:派姆单抗治疗儿科各类肿瘤的疗效

派姆单抗已被批准用于治疗成人晚期癌症,但尚无派姆单抗用于儿科癌症患者的疗效和安全性的相关信息。现研究人员开展一项1-2期开放性研究,以明确派姆单抗用于晚期小儿癌症推荐的2期剂量、安全性和抗肿瘤活性。从多个国家的30家医院招募6-17岁的黑色素瘤或PD-L1阳性的复发性或难治性实体肿瘤或淋巴瘤患儿,要求Lansky Play/Karnofsky表现状态评分≥50,予以派姆单抗 静脉注射,初始剂量2m

Lancet Haematol:产前治疗or产后治疗,霍奇金淋巴瘤孕妇患者及新生儿的生存预后有什么不同?

目前关于妊娠期间诊断为霍奇金淋巴瘤的患者及其新生儿预后结局的研究不足,对霍奇金淋巴瘤产前管理的相关报道也不多。近日,发表在Lancet Haematology的一项回顾性队列研究探讨了妊娠期间诊断为霍奇金淋巴瘤患者产前治疗或产后治疗对孕产妇及其新生儿生存预后的影响。

Brentuximab Vedotin在霍奇金淋巴瘤中疗效显著,联合免疫治疗将带来更大突破

第15届国际淋巴瘤大会(ICML)在瑞士·卢加诺隆重召开。作为世界性淋巴瘤学术盛会,ICML汇聚了全球最顶级的淋巴瘤专家及学者。霍奇金淋巴瘤(HL)领域,本次ICML报道了多项最新研究结果。针对HL相关话题以及CD30单抗Brentuximab Vedotin(以下简称“BV”)在HL中的疗效及安全性进行了介绍,详情如下。

JCO:PD-L1用于新诊断的晚期经典霍奇金淋巴瘤

Nivolumab用于新诊断的晚期经典霍奇金淋巴瘤:II期CheckMate205研究中的安全性和有效性

JSH实践指南:血液恶性肿瘤—Ⅱ淋巴瘤:霍奇金淋巴瘤

2018年日本血液学会(JSH)血液恶性肿瘤—淋巴瘤指南,本文为霍奇金淋巴瘤管理指南,主要涉及各阶段霍奇金淋巴瘤的管理等内容。

NCCN临床实践指南:霍奇金淋巴瘤(2019.V2)

2019年7月,美国国家综合癌症网络(NCCN)发布了霍奇金淋巴瘤指南,2019年第2版,指南主要内容涉及: 指南更新 诊断和检查 经典霍奇金淋巴瘤的临床分期 完成治疗后随访和副作用监测 耐药或疑似复发经典型霍奇金淋巴瘤 I–II期典型霍奇金淋巴瘤不利的风险因素 系统治疗原则 放射治疗原则 PET-5绩点量表 复发或难治性疾病的系统治疗原则 老年典型霍奇金淋巴瘤的管理 分期

拓展阅读

BJH:III/IV期经典霍奇金淋巴瘤患者的治疗偏好:CONNECT横断面调查的结果

这些调查结果突出了患者的治疗偏好和治疗目标的差异以及基于患者年龄的长期副作用问题

儿童霍奇金淋巴瘤治疗方案对晚期心脏毒性的影响

本研究定制了这些模型,将其应用于在最近的儿童肿瘤组(COG)试验中接受治疗的HL患者,目的是(1)确定随着试验的发展,晚期心脏风险是否会降低;(2)确定可能产生最大益处的进一步干预措施。

晚期霍奇金淋巴瘤中期评估PET 阳性残留组织的模式与治疗失败的风险德国霍奇金研究小组的 HD18 随机 III 期试验分析

本研究旨在描述HD18研究中PET-2阳性残留组织的模式,并确定与单灶性或少灶性疾病相比,多灶性残留病是否与较差的无进展生存期(PFS)相关。

【Cancer Biol Med】霍奇金淋巴瘤治疗的2023年新进展

《Cancer Biology & Medicine》近日发表一篇文章,讨论了HL中开发新型治疗方案的相关进展,通讯作者为天津医科大学肿瘤医院张会来教授和王先火教授。

JCO:综述:青少年和青壮年经典型霍奇金淋巴瘤患者的治疗

近日发表一篇综述,聚焦于AYA HL的现状,特别关注儿科和肿瘤内科的合作及多学科合作,以指导患者最佳治疗。现翻译全文供参考。 

【Leukemia】早期低危霍奇金淋巴瘤PET2驱动治疗:3期HD16研究5年随访结果

近日《Leukemia》发表了该研究随访64个月长期随访的最终分析结果。